^
Association details:
| Biomarker: | ARSI overexpression |
|---|---|
| Cancer: | Head and Neck Cancer |
| Drug: | daporinad (APO866) (Nicotinamide phosphoribosyltransferase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Arylsulfatase I is a prognostic biomarker for head and neck squamous cell carcinoma and Pan-cancer
Published date:
07/23/2022
Excerpt:
Arylsulfatase I was highly expressed in 15 cancer types, with significant expressions in HNSC….Elevated ARSI expressions conferred poor tolerance to daporinad and sinularin, but increased cell sensitivity to dasatinib and XAV939.
DOI:
10.1002/jcla.24600
